Aduro Biotech (ADRO) Files $86.25M IPO

Aduro Biotech, Inc. (Nasdaq: ADRO) filed a registration with the U.S. SEC for an IPO of its Common Stock. The proposed maximum offering price is $86.25 million. The company plans to list on the Nasdaq Global Market under the symbol, ADRO.

The offering is being made via BofA Merrill Lynch, Leerink Partners, William Blair, and Canaccord Genuity.

Aduro Biotech is a clinical-stage immuno-oncology company focused on the development of first-in-class technology platforms designed to stimulate robust and durable immune responses against cancer, and our lead product candidate is in a randomized controlled Phase 2b clinical trial in metastatic pancreatic cancer.

You May Also Be Interested In

• Exclusive: National Vision’s CEO on why the market got post-Q1 selloff wrong
• RedHill Biopharma sets $6M private placement with warrant upside
• Motorsport Games names Peter Hansen-Chambers as CFO effective July 1